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] and PAR1-AP [TRAP, 32 μmol L after stimulation with PAR1-AP (by approximately 20% and 50%, respectively), but remained relatively unchanged when ADP was used as agonist (n = 9). The platelet count-dependent effects observed with PAR1-AP were eliminated when samples were pre-incubated with apyrase, implying that reduced purinergic signaling was the main underlying factor (n = 5). Both aggregometry-based PFTs showed a 50% reduction at 50 × 10 9 L −1 and more than 80% reduction at 10 × 10 9 L −1 , irrespective of agonist used (n = 7).
Conclusions:
Although FC-PFT is generally preferable to aggregometry-based PFTs in situations with low sample platelet counts, a careful optimization of experimental parameters is still required in order to eliminate platelet count-related effects.
K E Y W O R D S
platelet activation, platelet aggregation, platelet count, platelet function tests, thrombocytopenia with a roughly proportional relationship between sample platelet concentration and the signal-to-noise ratio. 7, 13 However, few studies has included an attempt to quantify the effects when sample platelet counts drop below 50 × 10 9 L −1 , levels commonly encountered in samples from patients with conditions associated with thrombocytopenia. For total comparability, all tests were performed in parallel using the standard reagents and conditions for the commercially available MEA test. Hirudin was used as anticoagulant, as platelet responses involving ADP have been shown to be artificially enhanced in the low calcium environment in citrated blood. 15 
| INTRODUCTION

| MATERIALS AND METHODS
Venous blood was collected from healthy volunteers not taking any drugs that interfere with platelet function for the last 10 days. Blood was collected in hirudin tubes (Roche Diagnostics GmbH, Mannheim, Germany). The procedure for blood collection was approved by the regional ethics review board in Linköping, Sweden.
To obtain platelet-rich plasma (PRP), whole blood was centrifuged at 150 g for 15 min at room temperature. After harvesting PRP and discarding of the remaining buffy coat, these tubes were further centrifuged at 2500 g for 15 min to obtain red blood cells. Separate tubes were immediately centrifuged at 2500 g for 15 min to obtain platelet-poor plasma (PPP). Cell counting of the content of the different fractions was performed using a Swelab Alfa (Boule Diagnostics AB, Spånga Sweden).
Blood and PRP with platelet counts of 200, 100, 50, and 10 × 10
were created by combining the components in different proportions, calculated from the platelet counts for the different components. For whole blood samples, the hematocrit was adjusted to 40%.
LTA was performed in reconstituted PRP using a Chronolog instrument (Model 560, Chrono-Log, Haverston, PA) and MEA in reconstituted whole blood using the Multiplate instrument (Roche Diagnostics GmbH) according to manufacturer instructions. For consistency, the Multiplate TRAPtest and ADPtest reagents were
Essentials
• Data comparing the effect of low sample platelet counts (PC) in different platelet function tests (PFTs) is scarce.
• This study compares the effects of decreasing PCs on results from three common PFTs.
• As expected, results from aggregometry-based PFTs were heavily affected by low PCs.
• For flow cytometry PFTs, smaller effects were observed, affecting parameters dependent on paracrine (cell-to-cell) signaling.
used for platelet activation in all experiments in the same final con- 
| Statistics
Statistical analysis was performed using GraphPad Prism v. 
| RESULTS AND DISCUSSION
For FC-PFT, decreasing sample platelet counts were associated with statistically significant but slight increases in the binding of activation markers after stimulation with ADP ( Figure 1A,B) .
In contrast, decreasing sample platelet counts were associated with significantly decreased PAC-1 binding after activation with Figure 2D ). Decreasing sample platelet counts were also associated with a slight decrease in P-selectin exposure, but this effect was much less pronounced and significant only at a platelet count of 10 × 10 9 L −1 (approximately 80%-85% of the value at 200 × 10 9 L −1 , Figure 2D) . Interestingly, the association observed between sample platelet count and FC-PFT after stimulation with PAR1-AP was almost completely abolished when apyrase was added to the samples before stimulation ( Figure 1E,F PFT. In fact, we even observed a slight increase in response to ADP at lower platelet counts (Figure 2A,B) . This strongly suggests that the PPP we used did not have any detrimental effects on platelet reactivity.
Our finding that PAC-1 binding was more affected by decreasing platelet counts than P-selectin exposure is consistent with the notion that decreased ADP signaling represents the major underlying mechanism, as alpha granule release (resulting in P-selectin exposure) is a very early event in platelet activation, whereas stable glycoprotein activation is associated with more sustained platelet activation, dependent on autacoid co-stimulation.
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In conclusion, our study implies that FC-PFT is generally preferable to aggregometry-based PFTs in situations with low platelet counts and also provides guidance regarding the magnitude of changes to be expected at different platelet counts. We conclude that in order to minimize the effect of low sample platelet counts on results from FC-PFTs, tests should be performed using ADP as agonist or, when using agonists such as PAR1-AP which are partially dependent on paracrine stimulation, in the presence of apyrase to eliminate the contribution of ADP signaling. We also show that Pselectin exposure is a more robust activation marker than PAC-1 binding in situations with low platelet counts. One caveat in this regard, is that we only tested one agonist concentration for each of the agonists used. Thus, it would be desirable to confirm our findings in future studies including a broader range of agonist concentrations. that the risk of spontaneous bleeding events in severely thrombocytopenic patients is not directly related to the platelet count, 19, 20 and that the risk of surgical or obstetric bleeding is higher in patients with inherited disorders of platelet function than in inherited disorders of platelet numbers. 21, 22 Also, in another recent study, it was found that although there was an increased incidence of bleeding events during delivery in women with inherited thrombocytopenia and a platelet count of <50 × 10 9 L −1 , the increased incidence did not seem to be linearly correlated with 
